MGNX News and Press, MacroGenics Inc. From 07/29/21

MacroGenics (NASDAQ:MGNX): Q2 GAAP EPS of -$0.66 misses by $0.08. Revenue of $30.8M (+52.0% Y/Y) misses by $1.35M.  Cash, cash equivalents and marketable securities as of June 30, 2021 were $297.3M, compared to $272.5M as of December 31, 2020. MacroGeni...

Upcoming MGC018 and margetuximab MAHOGANY clinical data presentations at European Society for Medical Oncology (ESMO) Meeting Conference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, Md., July 29, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX)...

ROCKVILLE, MD, July 22, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its finan...

Shanghai's Zai Lab announced a four-drug immuno-oncology deal with MacroGenics worth over $1.4 billion. Beijing's LinkDoc Technology, an AI-driven healthcare company based on cancer patient data, filed to IPO on the NASDAQ exchange. Suzhou Innovent Bio has dosed the first person i...

MacroGenics (MGNX) and Zai Lab (ZLAB) have entered into an exclusive collaboration and license agreement involving up to four immuno-oncology molecules.MacroGenics provides rights to Zai Lab for its DART and TRIDENT multi-specific platforms and a lead research program targeting solid tumors. ...

Zai Lab granted combination of regional Asian and global rights for up to four CD3- or CD47-based bispecific molecules MacroGenics provides rights to Zai Lab for its DART® and TRIDENT® multi-specific platforms and a lead research program targeting solid tumors ...

Zai Lab granted combination of regional Asian and global rights for up to four CD3- or CD47-based bispecific molecules MacroGenics provides rights to Zai Lab for its DART® and TRIDENT® multi-specific platforms and a lead research program targeting solid tumors ...

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to invest in multiple biotech companies via one vehicle. The life science sector certainly holds a risk factor, and ETFs are a good wa...

Gainers: Ra Medical Systems RMED +54%, Liminal BioSciences LMNL +42%, Atossa Therapeutics (ATOS) +27%, Bionano Genomics BNGO +20%, Clover Health Investments (CLOV) +16%.Losers: Cabaletta Bio (CABA) -10%, MacroGenics (MGNX) -8%, Purple Bio...

ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...